181 related articles for article (PubMed ID: 23326194)
41. Integrating oxaliplatin with highly luminescent carbon dots: an unprecedented theranostic agent for personalized medicine.
Zheng M; Liu S; Li J; Qu D; Zhao H; Guan X; Hu X; Xie Z; Jing X; Sun Z
Adv Mater; 2014 Jun; 26(21):3554-60. PubMed ID: 24634004
[TBL] [Abstract][Full Text] [Related]
42. Nanotechnology and nanomedicine: going small means aiming big.
Teli MK; Mutalik S; Rajanikant GK
Curr Pharm Des; 2010 Jun; 16(16):1882-92. PubMed ID: 20222866
[TBL] [Abstract][Full Text] [Related]
43. Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision.
Sahakyan N; Haddad A; Richardson S; Forcha-Etieundem V; Christopher L; Alharbi H; Campbell R
Anticancer Agents Med Chem; 2017; 17(8):1033-1039. PubMed ID: 28042778
[TBL] [Abstract][Full Text] [Related]
44. [Antibody-drug conjugate--a new age for personalized cancer treatment].
Bertholjotti I
Chimia (Aarau); 2011; 65(9):746-8. PubMed ID: 22026193
[No Abstract] [Full Text] [Related]
45. Norwegian Cancer Genomics Consortium: a platform for research on personalized cancer medicine in a public health system.
Myklebost O
Drug Discov Today; 2015 Dec; 20(12):1419-21. PubMed ID: 26520668
[No Abstract] [Full Text] [Related]
46. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
47. Exploiting tumor vulnerabilities: epigenetics, cancer metabolism and the mTOR pathway in the era of personalized medicine.
Muñoz-Pinedo C; González-Suárez E; Portela A; Gentilella A; Esteller M
Cancer Res; 2013 Jul; 73(14):4185-9. PubMed ID: 23687347
[TBL] [Abstract][Full Text] [Related]
48. Enabling individualized therapy through nanotechnology.
Sakamoto JH; van de Ven AL; Godin B; Blanco E; Serda RE; Grattoni A; Ziemys A; Bouamrani A; Hu T; Ranganathan SI; De Rosa E; Martinez JO; Smid CA; Buchanan RM; Lee SY; Srinivasan S; Landry M; Meyn A; Tasciotti E; Liu X; Decuzzi P; Ferrari M
Pharmacol Res; 2010 Aug; 62(2):57-89. PubMed ID: 20045055
[TBL] [Abstract][Full Text] [Related]
49. Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine.
Wang Z; Liu X; Ho RL; Lam CW; Chow MS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27399658
[TBL] [Abstract][Full Text] [Related]
50. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer.
Beckman RA; Schemmann GS; Yeang CH
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14586-91. PubMed ID: 22891318
[TBL] [Abstract][Full Text] [Related]
51. Toward a Personalized Use of Paclitaxel.
Russo GL
Recent Pat Anticancer Drug Discov; 2019; 14(4):296-297. PubMed ID: 31920185
[No Abstract] [Full Text] [Related]
52. Nanotechnology as a Delivery Tool for Precision Cancer Therapies.
Sharma B; Crist RM; Adiseshaiah PP
AAPS J; 2017 Nov; 19(6):1632-1642. PubMed ID: 29019032
[TBL] [Abstract][Full Text] [Related]
53. Cancer nanomedicines: closing the translational gap.
Gabizon A; Bradbury M; Prabhakar U; Zamboni W; Libutti S; Grodzinski P
Lancet; 2014 Dec; 384(9961):2175-6. PubMed ID: 25625382
[No Abstract] [Full Text] [Related]
54. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
55. Nanomedicine for cancer therapy.
Amiji MM
Pharm Res; 2011 Feb; 28(2):181-6. PubMed ID: 20845066
[No Abstract] [Full Text] [Related]
56. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
57. Molecular image-guided theranostic and personalized medicine 2014.
Zhang H; Tian M; Carrio I; Civelek AC; Fujibayashi Y
Biomed Res Int; 2015; 2015():258612. PubMed ID: 25883947
[No Abstract] [Full Text] [Related]
58. Nanomedicine: a new frontier in cancer therapeutics.
Lee PY; Wong KK
Curr Drug Deliv; 2011 May; 8(3):245-53. PubMed ID: 21291378
[TBL] [Abstract][Full Text] [Related]
59. Targeted nanotheranostics for personalized cancer therapy.
Diou O; Tsapis N; Fattal E
Expert Opin Drug Deliv; 2012 Dec; 9(12):1475-87. PubMed ID: 23092183
[TBL] [Abstract][Full Text] [Related]
60. Multifunctional nanomedicine platforms for cancer therapy.
Zhang H
J Nanosci Nanotechnol; 2012 May; 12(5):4012-8. PubMed ID: 22852341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
